1461083976-b1b5f8e3-5f05-4fe3-b33b-8ac2da715a76

1. A volcano food fountain, comprising:
a fountain base having a bowl;
a scoop carried by said fountain base in said bowl;
a servo motor operably engaging said scoop and adapted to raise and lower said scoop in said bowl;
a simulated volcano carried by said fountain base in said bowl;
a pump provided in said simulated volcano and communicating with said bowl;
a volcano opening provided in said simulated volcano and communicating with said pump; and
a tray carried by said fountain base.
2. The volcano food fountain of claim 1 wherein said tray has a generally annular shape.
3. The volcano food fountain of claim 2 wherein said tray is rotatable with respect to said fountain base.
4. The volcano food fountain of claim 3 further comprising a tray drive motor operably engaging said tray for rotating said tray on said fountain base.
5. The volcano food fountain of claim 1 further comprising a decorative surface carried by said fountain base between said tray and said bowl.
6. The volcano food fountain of claim 5 further comprising simulated vegetation provided on said decorative surface.
7. A volcano food fountain, comprising:
a fountain base having a bowl;
a simulated volcano carried by said fountain base in said bowl;
a pump provided in said simulated volcano and communicating with said bowl;
a volcano opening provided in said simulated volcano and communicating with said pump;
a tray carried by said fountain base;
a ring gear carried by said tray;
a drive gear meshing with said ring gear; and
a tray drive motor carried by said fountain base and drivingly engaging said drive gear.
8. The volcano food fountain of claim 7 wherein said tray has a generally annular shape.
9. The volcano food fountain of claim 8 further comprising a tray slot provided in said fountain base and wherein said tray is provided in said tray slot.
10. The volcano food fountain of claim 7 further comprising a scoop carried by said fountain base in said bowl.
11. The volcano food fountain of claim 10 further comprising a servo motor operably engaging said scoop and adapted to raise and lower said scoop in said bowl.
12. The volcano food fountain of claim 7 further comprising a decorative surface carried by said fountain base between said tray and said bowl.
13. The volcano food fountain of claim 12 further comprising simulated vegetation provided on said decorative surface.
14. A volcano food fountain, comprising:
a fountain base having a bowl;
a simulated volcano carried by said fountain base in said bowl;
a pump provided in said simulated volcano and communicating with said bowl;
a volcano opening provided in said simulated volcano and communicating with said pump;
a tray carried by said fountain base;
a pair of scoop slots provided in said fountain base;
a pair of scoop arms extending through said pair of scoop slots, respectively, and pivotally carried by said fountain base;
a scoop carried by said pair of scoop arms;
a servo motor carried by said base; and
a drive belt coupling said servo motor to said pair of scoop arms.
15. The volcano food fountain of claim 14 wherein said tray has a generally annular shape.
16. The volcano food fountain of claim 15 further comprising a tray drive motor carried by said fountain base and operably engaging said tray for rotating said tray with respect to said fountain base.
17. The volcano food fountain of claim 14 further comprising a decorative surface carried by said fountain base between said tray and said bowl.
18. The volcano food fountain of claim 17 further comprising simulated vegetation provided on said decorative surface.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of analyzing a hollow anatomical structure of interest for percutaneous implantation, comprising the steps of:
acquiring image data relating to an anatomical region of interest that at least partially includes the anatomical structure of interest;
generating a segmented model of the anatomical region of interest using the acquired image data;
obtaining one or more images of the anatomical structure of interest by sectioning out intervening anatomical structures from the segmented model;
identifying one or more pertinent landmarks of the anatomical structure of interest in the one or more acquired images;
measuring at least one of a circumference, a maximal diameter, or a minimal diameter of one or more features of the anatomical structure of interest contained in the one or more acquired images to determine an anatomical structure size; and
reconciling the anatomical structure size and an implant size.
2. The method of claim 1, wherein he acquired image data comprises computed tomography (CT) data and the segmented model comprises a segmented CT model.
3. The method of claim 1, further including the step of determining a point of access for percutaneous implantation.
4. The method of claim 3, further comprising verifying that the point of access does not intersect any anatomical structures by removing one or more layers of the segmented model.
5. The method of claim 3, further comprising determining a trajectory angle at the point of access.
6. The method of claim 1, further including the step of estimating an anatomical structure volume.
7. The method of claim 1, wherein the anatomical structure of interest is a mitral valve.
8. The method of claim 7, wherein the one or more pertinent landmarks comprise one or more of: a mitral valve leaflet tip and an intersection point of the mitral valve leaflets and the annulus of the mitral valve.
9. The method of claim 1, wherein the anatomical structure of interest is a left atrial appendage.
10. The method of claim 9, wherein the one or more landmarks comprise one or more of: a pulmonary vein; a location of the Coumadin ridge; the transverse pericardial sinus; the circumflex artery; the mitral valve; the left atrium, the interatrial septum, and the superior vena cava and inferior vena cava transition into the interatrial septum.
11. The method of claim 1, wherein the anatomical structure of interest is a tricuspid inferior vena cava valve.
12. The method of claim 11, wherein the one or more landmarks comprise one or more of:
the right atrium-inferior vena cava plane, the inferior vena cava ostium, and the first hepatic vein.
13. The method of claim 1, further including creating a computer aided design (CAD) model of at least a portion of the anatomical structure of interest, and the reconciling step comprises importing a model of the implant into the CAD model.
14. The method of claim 1, further including acquiring a printed model of at least a portion of the anatomical structure of interest, and the reconciling step comprises inserting a physical model of the implant into the printed model.
15. A method of analyzing a hollow anatomical structure of interest for percutaneous implantation, comprising the steps of:
acquiring a model of an anatomical region of interest that at least partially includes the anatomical structure of interest, wherein the model is generated from image data relating to the anatomical region of interest;
obtaining one or more images of the anatomical structure of interest by sectioning out intervening anatomical structures from the model;
acquiring data relating to the anatomical structure of interest from the one or more images of the anatomical structure of interest; and
determining a size of an implant to be implanted into the anatomical structure of interest based on the acquired data.
16. The method of claim 15, wherein the step of acquiring data relating to the anatomical structure of interest comprises acquiring one or more measurements relating to one or more features of the anatomical structure of interest, and the determining step comprises determining the size of the implant based on the acquired measurement(s).
17. The method of claim 15, wherein the step of acquiring data relating to the anatomical structure of interest comprises acquiring data relating to a blood volume of the anatomical structure of interest.
18. The method of claim 17, further comprising generating a model of the anatomical structure of interest based on the blood volume data, and wherein the determining step comprises determining the size of the implant using the model generated from the blood volume data.
19. The method of claim 15, wherein the model generated from the blood volume data comprises a model of the interior surface of the anatomical structure of interest.
20. A non-transitory, computer-readable storage medium storing instructions thereon that when executed by one or more electronic processors causes the one or more processors to carry out the method of:
acquiring a model of an anatomical region of interest that includes the anatomical structure of interest, wherein the model is generated from image data relating to the anatomical region of interest;
obtaining one or more images of the anatomical structure of interest by sectioning out intervening anatomical structures from the model;
acquiring data relating to the anatomical structure of interest; and
determining a size of an implant to be implanted into the anatomical structure of interest based on the acquired data.

1461083965-35f17cc6-cea8-4707-b8fb-9618b07c1203

1. A joint protecting device for a baby stroller, said device has a pair of guarding housings on the outer surface of two joints on the two lateral sides of the baby stroller, wherein
said joints each is fixed on a top of a lower strut of said baby stroller, and is provided for pivoting of an upper strut thereon, such that said lower strut and said upper strut pivot relatively to each other; said joint has an axle and a recess to allow one of said guarding housings to be pivotally provided on said joint;
each of said guarding housings is provided above one of said joints, and is provided with a linking hole being slipped over said upper strut, thereby said upper strut is adapted to pivotally connecting to said joint after extending through said linking hole; when said upper strut is rotated relatively to said lower strut on said joint, through the linking hole, it makes said guarding housing rotate about the axle of said joint to sustainingly obstruct a gap with an angle formed between said joint and said upper strut.
2. The joint protecting device for a baby stroller as stated in claim 1, wherein said joint is in a round shape, said guarding housing is in a shape in corresponding to contour of said joint, and its vertical sectional top portion is in an arc shape.
3. The joint protecting device for a baby stroller as stated in claim 1, wherein said guarding housing forms two walls at two lateral sides of said joint, and forms an obstructing plate above said joint, said linking hole is provided on said obstructing plate; said two walls each has an axial hole near its central area, said axial hole is pivotally connect to said axle of said joint.
4. The joint protecting device for a baby stroller as stated in claim 3, wherein said joint has thereon a recess to allow pivoting of said upper strut, a bottom of said recess is in a shape in corresponding to that of said upper strut, said obstructing plate obstructs above said recess.
5. The joint protecting device for a baby stroller as stated in claim 1, wherein said linking hole is in a shape meeting that of said upper strut.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of Formula (Ia):
or pharmaceutically acceptable salt thereof, wherein:
R1a is selected from H and halogen;
R3a is selected from C2-6 heterocycloalkyloxy and C1-6 heteroaryl-C1-4-alkoxy; wherein said C2-6 heterocycloalkyloxy and C1-6 heteroaryl-C1-4-alkoxy are each optionally substituted by a Rw group;
R4a is selected from H, a thiazole ring, a pyrazole ring, a triazole ring, a tetrazole ring, a pyridine ring, C3-6 cycloalkyl, cyano, halogen, C2-6 alkynyl, C1-6 heteroaryl-C1-4-alkyl, C1-6 heteroaryl-C1-4-alkynyl, \u2014C(\u2550O)Ra, and \u2014C(\u2550O)NRbRc; wherein said thiazole ring, pyrazole ring, triazole ring, tetrazole ring, pyridine ring, C1-6 heteroaryl-C1-4-alkyl and C1-6 heteroaryl-C1-4-alkynyl are each optionally substituted by 1 or 2 independently selected Rx\u2033 groups;
Ar1a is selected from phenyl optionally substituted at the meta position by one Ry\u2032 or, alternatively, at the para position by one Ry\u2033 group;
each Rw is independently selected from halogen, C1-6 alkyl, amino, C1-6 alkylamino, di-C1-4-alkylamino, C1-6 alkoxycarbonyl, and C1-6 alkylcarbamyl; wherein said C1-6 alkyl and C1-6 alkylamino are each optionally substituted by a group selected from hydroxyl, C1-6 alkoxy, amino, C1-6 alkylamino, and di-C1-4-alkylamino;
each Rx\u2033 is independently selected from halogen, hydroxyl, C1-6 alkyl, C1-6 alkoxycarbonyl, and carbamyl; wherein said C1-6 alkyl and C1-6 alkoxycarbonyl are each optionally substituted by a group selected from hydroxyl, amino, C1-4 alkylamino, and aminosulfonyl;
Ry\u2032 is selected from halogen, C1-6 alkoxy, C1-6 alkyl, carbamyl, aminosulfonyl, and C1-6 alkylsulfonylamino; wherein said C1-6 alkyl and C1-6 alkoxy are each substituted by 1 or 2 groups independently selected from hydroxyl, amino, C1-4 alkylamino, and aminosulfonyl;
Ry\u2033 is selected from C1-6 haloalkyl;
Ra is selected from H, C1-6 alkoxy and C2-6 heterocycloalkyl;
Rb is selected from H and C1-6 alkyl; and
Rc is selected from C1-6 alkyl, C3-6 cycloalkyl, C1-6 heteroaryl, C2-6 heterocycloalkyl, C2-6 heterocycloalkyl-C1-4-alkyl, and C1-6 heteroaryl-C1-4-alkyl; wherein said C1-6 alkyl is optionally substituted by a group selected from hydroxyl and C1-4 alkoxy;
provided that:
(a) when R3a is piperidin-4-yloxy or N-methylpiperidin-4-yloxy, then R4 is not selected from thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, 5-methylthiazol-2-yl, 5-(hydroxymethyl)thiazol-2-yl, 5-(hydroxymethyl)thiazol-4-yl, pyridin-2-yl, pyridin-4-yl, pyridin-3-yl, 4-methylpyridin-3-yl, 5-chloropyridin-4-yl, 3-methylpyridin-2-yl, and 1-methylpyrazol-5-yl;
(b) when R4a is ethynyl and Ar1a is 3-fluorophenyl, then R3 is not selected from pyridin-3-ylmethoxy, 6-chloropyridin-3-ylmethoxy, pyridin-2-ylmethoxy, pyridin-4-ylmethoxy, 1-(pyridin-4-yl)ethoxy, 6-methoxypyridin-2-ylmethoxy, thiazol-5-ylmethoxy, pyrazin-2-ylmethoxy, 5-methylisooxazol-3-yl, azetidin-3-yloxy, N-methylazetidin-3-yloxy, N-isopropylazetidin-3-yloxy, pyrrolidin-3-yloxy, N-methyl, and pyrrolidin-3-yloxy;
(c) when R4a is ethynyl, then Ar1a is not selected from 3-(2-hydroxypropan-2-yl)phenyl, 3-(1-hydroxyethyl)phenyl, 3-amino sulfonylphenyl, phenyl, 3-(methylsulfonylamino)phenyl, 3-(N,N-dimethylaminomethyl)phenyl, 3-aminosulfonylphenyl, and 3-carbamylphenyl;
(d) when R4a is thiazol-2-yl, then Ar1a is not selected from 3-(methylaminosulfonyl)phenyl, 3-chlorophenyl, 3-carbamylphenyl, 3-fluorophenyl, 2-(hydroxypropan-2-yl)phenyl, 1-hydroxyethyl, 3-aminosulfonylphenyl, and phenyl;
(e) when R4a is thiazol-2-yl and Ar1a is 3-fluorophenyl, then R3 is not selected from pyridin-3-ylmethoxy, 6-chloropyridin-3-ylmethoxy, 2-chloropyridin-4-ylmethoxy, 5-methylisooxazol-3-yl, azetidin-3-yloxy, N-methylazetidin-3-yloxy, N-isopropylazetidin-3-yloxy, pyrrolidin-3-yloxy, N-methyl, pyrrolidin-3-yloxy, piperidin-4-yloxy, and N-methylpiperidin-4-yloxy;
(f) when R4a is bromo, then Ar1a is not selected from phenyl, 3-fluorophenyl, 2-(hydroxypropan-2-yl)phenyl, 1-hydroxyethyl, and 3-amino sulfonylphenyl ;
(g) when R4a is cyano, then R3a is not selected from pyridin-4-ylmethoxy, pyridin-2-ylmethoxy, and 6-methoxypyridin-2-ylmethoxy;
(h) when R4a is cyclopropyl, then R3a is not selected from azetidin-3-yloxy; and
(i) when R4a is hydrogen, then Ar1a is 3-(aminosulfonyl)phenyl.
2. The compound according to claim 1, or pharmaceutically acceptable salt thereof, wherein Ar1a is selected from 3-fluorophenyl, 3-methylaminosulfonyl, 3-carbamylphenyl, 3-chlorophenyl, 4-difluoromethylphenyl, -(2-amino-n-propyl)methylphenyl, 3-(1-amino-3-hydroxy-n-propyl)phenyl, 3-(2-aminoethyl)phenyl, 3-(aminomethyl)phenyl, 3-(3-amino-1-hydroxy)phenyl, 3-(2-hydroxyethyl)phenyl, 3-(hydroxymethyl)phenyl, 3-methylaminosulfonyl, 3-(aminosulfonylmethyl)phenyl, 3-carbamylphenyl and 3-chlorophenyl.
3. The compound according to any one of claims 1 and 2, or pharmaceutically acceptable salt thereof, wherein R3a is selected from piperidin-4-yloxy, N-methylpiperidin-4-yloxy, N-(tert-butoxycarbonyl)piperidin-4-yloxy, 3-fluoropiperidin-4-yloxy, 2-(hydroxymethyl)piperidin-4-yloxy, N-(tert-butoxycarbonyl)piperidin-4-yl, 2-(N-methylcarbamyl)piperidin-4-yloxy, 6-methoxypyridin-3-ylmethoxy, 6-(N-methylamino)pyridin-3-ylmethoxy, 6-(N,N-dimethylamino)pyridin-3-ylmethoxy, 6-(N-(2-hydroxyethyl)amino)pyridin-3-ylmethoxy, 6-(N-(2-methoxyethyl)amino)pyridin-3-ylmethoxy, 6-(N-(2-aminoethyl)amino)pyridin-3-ylmethoxy, and pyridin-3-ylmethoxy; and
R4a is selected from ethynyl, bromo, cyano, cyclopropyl, thiazol-2-yl, pyridin-3-yl, 4-(hydroxymethyl)thiazol-2-yl, 1,2,3-triazol-5-yl, tetrazol-5-yl, pyrazol-2-yl, 5-methylpyrazol-2-yl, 2-(pyridin-2-yl)ethynyl, 2-(pyridin-2-yl)ethyl, 2-(pyridin-3-yl)ethynyl, 2-(pyridin-3-yl)ethyl, 4-(methoxycarbonyl)thiazol-2-yl, 4-carbamylthiazol-2-yl, \u2014C(\u2550O)Ra, and \u2014C(\u2550O)NRbRc.
4. The compound according to claim 1, or pharmaceutically acceptable salt thereof, wherein:
R1a is selected from H;
Ar1a is 3-fluorophenyl;
R3a is selected from 3-fluoropiperidin-4-yloxy, 2-(hydroxymethyl)piperidin-4-yloxy, N-(tert-butoxycarbonyl)piperidin-4-yl, and 2-(N-methylcarbamyl)piperidin-4-yloxy; and
R4a is selected from thiazol-2-yl and pyridin-3-yl.
5. The compound according to claim 1, or pharmaceutically acceptable salt thereof, wherein:
R1a is selected from H;
Ar1a is 3-fluorophenyl;
R3a is selected from 6-methoxypyridin-3-ylmethoxy, 6-(N-methylamino)pyridin-3-ylmethoxy, 6-(N,N-dimethylamino)pyridin-3-ylmethoxy, 6-(N-(2-hydroxyethyl)amino)pyridin-3-ylmethoxy, 6-(N-(2-methoxyethyl)amino)pyridin-3-ylmethoxy, and 6-(N-(2-aminoethyl)amino)pyridin-3-ylmethoxy; and
R4a is ethynyl.
6. The compound according to claim 1, or pharmaceutically acceptable salt thereof, wherein:
R1a is selected from H;
Ar1a is selected from 3-(2-amino-n-propyl)methylphenyl, 3-(1-amino-3-hydroxy-n-propyl)phenyl, 3-(2-aminoethyl)phenyl, 3-(aminomethyl)phenyl, 3-(3-amino-1-hydroxy)phenyl, 3-(2-hydroxyethyl)phenyl, and 3-(hydroxymethyl)phenyl;
R3a is selected from pyridin-3-ylmethoxy; and
R4a is selected from ethynyl and bromo.
7. The compound according to claim 1, or pharmaceutically acceptable salt thereof, wherein:
R1a is selected from H;
Ar1a is selected from 3-methylaminosulfonyl, 3-(aminosulfonylmethyl)phenyl, and phenyl;
R3a is selected from piperidin-4-yloxy; and
R4a is thiazol-2-yl and 4-(hydroxymethyl)thiazol-2-yl.
8. The compound according to claim 1, or pharmaceutically acceptable salt thereof, wherein:
R1a is selected from H;
Ar1a is 3-fluorophenyl
R3a is selected from piperidin-4-yloxy and N-(tert-butoxycarbonyl)piperidin-4-yloxy;
R4a is selected from \u2014C(\u2550O)Ra, and \u2014C(\u2550O)NRbRc;
Ra is selected from H, methoxy and morpholin-4-yl;
Rb is selected from H and methyl; and
Rc is selected from methyl, 2-hydroxyethyl, 2-methoxyethyl, tetrahydro-2H-pyran, tetrahydropyran-2H-methyl, 2-oxopyrrolidinylethyl, and pyridin-3-ylmethyl;
9. The compound according to claim 1, or pharmaceutically acceptable salt thereof, wherein:
R1a is selected from H;
Ar1a is 3-carbamylphenyl and 3-chlorophenyl;
R3a is selected from pyridin-4-ylmethoxy; and
R4a is selected from ethynyl and bromo.
10. A compound of Formula (IIa):
or pharmaceutically acceptable salt thereof, wherein:
R1 is selected from H and halogen
R2 is selected from H, halogen, and C1-6 alkoxy;
R3 is selected from H, \u2014OCH2-phenyl, \u2014O\u2014CH2-Het, \u2014OCH2\u2014CH2-Het, and \u2014O\u2014Hy; wherein Het is 6-membered heteroaryl which is optionally substituted by 1 or 2 groups independently selected from hydroxyl, C1-6 alkyl, C1-4 alkoxy, amino, C1-4 alkylamino, di-C1-4 alkylamino, and C1-6 alkylcarbamyl; Hy is 6-membered heterocycloalkyl, which is optionally substituted by 1 or 2 groups independently selected from hydroxyl, C1-6 alkyl, C1-4 alkoxy, amino, C1-4 alkylamino, di-C1-4 alkylamino, and C1-6 alkylcarbamyl; and phenyl is optionally substituted by 1 or 2 groups independently selected from hydroxyl, C1-6 alkyl, C1-4 alkoxy, amino, C1-4 alkylamino, di-C1-4 alkylamino, and C1-6 alkylcarbamyl;
R4 is selected from cyano, halogen, C1-6 alkyl, C2-6 alkynyl, C3-6 cycloalkyl, a thiazole ring, a pyrazole ring, and a pyridine ring; each of which is optionally substituted by 1 or 2 groups independently selected from hydroxyl, C1-6 alkyl, C1-4 alkoxy, amino, C1-4 alkylamino, and di-C1-4 alkylamino; wherein said C1-6 alkyl is further optionally substituted by 1 or 2 hydroxyl groups;
Ar1 is a moiety of Group (A), (B), or (C):
A is a pyrazole ring; which is optionally substituted by 1 or 2 groups independently selected from hydroxyl, C1-6 alkyl, C1-4 alkoxy, amino, C1-4 alkylamino, and di-C1-4 alkylamino;
A\u2032 is selected from -L2-Ar2 and -L1-Cy1;
A\u2033 is selected from L2a-Ar2a and Cy1a;
L1 is selected from a bond, \u2014O\u2014, \u2014C(\u2550O)\u2014, \u2014CH2C(\u2550O)\u2014, and \u2014CH2\u2014; wherein the left end of the linker is attached to the phenyl ring and the right end of the linker is attached to Cy1;
Cy1 is selected from a morpholine ring, a tetrahydro-2H-pyran ring, a pyrrolidine ring, a 2-oxopyrrolidine ring, and a piperidine ring, each of which is optionally substituted by 1 or 2 groups independently selected from halogen, hydroxyl, C1-6 alkyl, C1-4 alkoxy, amino, C1-4 alkylamino, di-C1-4 alkylamino, C1-6 alkylcarbonyl, and C1-6 alkoxycarbonyl;
Cy1a is selected from a morpholine ring, a 2-oxopyrrolidine ring and a piperidine ring; each of which is optionally substituted by 1 or 2 groups independently selected from halogen, hydroxyl, C1-6 alkyl, C1-4 alkoxy, amino, C1-4 alkylamino, di-C1-4 alkylamino, C1-6 alkylcarbonyl, and C1-6 alkoxycarbonyl;
L2 and L2a are each independently selected from a bond, \u2014O\u2014, and \u2014CH2\u2014; and
Ar2 is selected from a pyrazole ring, an oxazole ring, an imidazole ring, a triazole ring, a thiadiazole ring, a pyridine ring, and a pyrimidine ring; each of which is optionally substituted with 1, 2, or 3 groups independently selected from hydroxyl, C1-6 alkyl, C1-4 alkoxy, amino, C1-4 alkylamino, and di-C1-4 alkylamino;
Ar2a is selected from a pyrazole ring, a triazole ring, a pyridine ring, and a pyrimidine ring; each of which is optionally substituted with 1 or 2 groups independently selected from hydroxyl, C1-6 alkyl, C1-4 alkoxy, amino, C1-4 alkylamino, and di-C1-4 alkylamino;

provided that:
(i) when R1 and R2 are each H, R4 is thiazol-2-yl, R3 is optionally substituted piperidin-4-yloxy, and Ar1 is a moiety of Group (A), then A\u2032 is not selected from 1,2,4-triazol-1-ylmethyl, 1-methylpyrazol-3-yl, 2-oxopyrrolidinyl, oxazol-5-yl, pyrazol-1-yl, 1-methyl-1,2,4-triazol-2-yl, morpholin-4-ylcarbonylmethyl, imidazol-2-yl, 2-methylthiazol-4-yl, 1,3,5-trimethylpyrazol-4-yl, pyrimidin-5-yl, 1,2,4-triazol-1-yl, 4,5-dimethyloxazol-2-yl, pyrimidin-5-yl, 2-methoxypyrimidin-5-yl, 6-methoxypyridin-3-yl, and pyridin-3-yl;
(ii) when R1 and R2 are each H, Ar1 is a moiety of Group (A), A\u2032 is selected from 1-methylpyrazol-3-yl, and R3 is selected from pyridin-3-ylmethoxy and pyrazin-2-ylmethoxy, then R4 is not thiazol-2-yl;
(iii) when R1 and R2 are each H, R4 is thiazol-2-yl, R3 is optionally substituted piperidin-4-yloxy, and Ar1 is a moiety of Group (B), then A\u2033 is not selected from morpholin-4-yl, morpholin-4-ylcarbonylmethyl, pyrimidin-5-yl, and pyrazol-1-ylmethyl;
(iv) when R1 and R2 are each H, R4 is bromo, R3 is pyridin-3-ylmethyl, and Ar1 is a moiety of Group (A), then A\u2032 is not piperidin-4-yl;
(v) when R1 and R3 are each H, R4 is bromo or ethynyl, R2 is isopropoxy, and Ar1 is a moiety of Group (A), then A\u2032 is not selected from 1-methyl-1,2,4-triazol-2-ylmethyl and morpholin-4-ylcarbonylmethyl;
(vi) when R1 and R2 are each H, R4 is cyclopropyl, bromo or ethynyl, R3 is chloro, and Ar1 is a moiety of Group (A), then A\u2032 is not 1,2,4-triazol-1-ylmethyl;
(vii) when R1 and R2 are each H, R4 is ethynyl, R3 is chloro, and Ar1 is a moiety of Group (A), then A\u2032 is not imidazol-2-yl, pyrazol-1-yl, and morpholin-4-ylmethyl;
(viii) when R1 and R3 are each H, R4 is ethynyl, R1 is chloro, and Ar1 is a moiety of Group (A), then A\u2032 is not selected from pyrazol-1-yl, oxazol-5-yl, imidazol-2-yl, morpholin-4-ylcarbonylmethyl, and 2-oxopyrrolidinyl;
(ix) when R1 and R2 are each H, R4 is ethynyl, R3 is H, and Ar1 is a moiety of Group (A), then A\u2032 is not selected from 1,2,4-triazol-1-ylmethyl, pyrazol-1-yl, oxazol-5-yl, imidazol-2-yl, 5-trifluoromethylimidazol-2-yl, imidazol-1-ylmethyl, 1,2,4-triazol-1yl-methyl, N-(ethoxycarbonyl)piperidin-4-yl, N-(methoxycarbonyl)piperidin-4-yl, N-(acetyl)piperidin-4-yl, N-methylpiperidin-4-yl, piperidin-4-yl, and 2-oxopyrrolidinyl;
(x) when R1 and R2 are each H, R4 is ethynyl, Ar1 is a moiety of Group (A), and A\u2032 is 1-methylpyrazol-3-yl, then R3 is not selected from pyridin-3-ylmethoxy, 2-pyridin-3-ylethoxy, thiazol-5-ylmethoxy, and pyrazin-2-ylmethoxy;
(xi) when R1 and R2 are each H, R4 is ethynyl, Ar1 is a moiety of Group (A), and A\u2032 is morpholin-4-ylmethyl, then R3 is not selected from pyridin-3-ylmethoxy and pyrazin-2-ylmethoxy;
(xii) when R1 and R2 are each H, R4 is ethynyl, Ar1 is a moiety of Group (A), and A\u2032 is oxazol-5-yl, then R3 is not selected from pyridin-3-ylmethoxy and pyrazin-2-ylmethoxy;
(xiii) when R1 and R2 are each H, R4 is ethynyl, R3 is H, and Ar1 is a moiety of Group (B), then A\u2033 is not selected from morpholin-4-ylmethyl and 2-oxopyrrolidinyl;
(xiv) when R1 and R2 are each H, R4 is ethynyl, R3 is chloro, and Ar1 is a moiety of Group (B), then A\u2033 is not selected from 2-oxopyrrolidinyl and morpholin-4-ylmethyl;
(xv) when R1 and R2 are each H, R3 is pyrazin-2-ylmethoxy, R4 is pyrazol-4-yl, and Ar1 is a moiety of Group (A), then A\u2032 is not 1-methylpyrazol-3-yl;
(xvi) when R1 and R2 are each H, R3 is piperidin-4-yloxy or N-methylpiperidin-4-yloxy, R4 is pyrazol-4-yl, and Ar1 is a moiety of Group (B), then A\u2033 is not morpholin-4-yl;
(xvii) when Ar1 is 3-morpholin-4-ylphenyl, then R3 is not H;
(xviii) when Ar1 is 4-morpholin-4-ylphenyl, then R4 is not selected from bromo, cyano, ethynyl, thiazol-2-yl, and 1H-pyrazol-4-yl;
(xix) when R1\u2032 is H, R2\u2032 is H, R3\u2032 is piperidin-4-yloxy, and R4\u2032 is 6-methoxypyridin-3-yl, and Ar1 is a moiety of Group (A), then A\u2032 is not 6-methoxypyridin-3-yl; and
(xx) when R1\u2032 is H, R2\u2032 is H, R3\u2032 is piperidin-4-yloxy, and R4\u2032 is 5-methoxypyridin-3-yl, and Ar1 is a moiety of Group (B), then A\u2033 is not 5-methoxypyridin-3-yl.
11. The compound according to claim 14, or pharmaceutically acceptable salt thereof, wherein Ar1 is a moiety of Group (A).
12. The compound according to claim 11, or pharmaceutically acceptable salt thereof, wherein A\u2032 is -L2-Ar2.
13. The compound according to claim 11, or pharmaceutically acceptable salt thereof, wherein A\u2032 is -L1-Cy1.
14. The compound according to claim 13, or pharmaceutically acceptable salt thereof, wherein:
A\u2032 is -L2-Ar2;
L2 is a bond;
Ar2 is selected from a pyridine ring, a pyrimidine ring, 1H-pyrazole ring, an oxazole ring, a 1,2,4-triazole ring, and a thiadiazole ring; each of which is optionally substituted by 1 or 2 groups independently selected from C1-6 alkyl and C1-6 alkoxy;
R1 is H;
R2 is H;
R3 is selected from \u2014O-phenyl, \u2014O\u2014CH2-Het, \u2014OCH2\u2014CH2-Het, and \u2014O\u2014Hy; wherein Het is a pyrazine ring, a pyridine ring, a pyrimidine ring, or a pyridazine ring; which is optionally substituted by a C1-6 alkyl group; Hy is piperidine ring, which is optionally substituted by a C1-6 alkyl group; and phenyl is optionally substituted by a C1-6 alkylcarbamyl group; and
R4 is selected from C2-6 alkynyl, thiazol-2-yl, 1H-pyrazol-4-yl, 1-methyl-1H-pyrazol-4-yl, and 1H-pyrazol-3-yl.
16. The compound according to claim 13, or pharmaceutically acceptable salt thereof, wherein:
A\u2032 is -L2-Ar2;
L2 is a bond;
Ar2 is selected from 5-methoxypyridin-3-yl, pyrimidin-5-yl, 1H-pyrazol-3-yl, 1H-pyrazol-5-yl, oxazol-5-yl, 1,2,4-triazol-5-yl, thiadiazol-4-yl, and 1-methyl-1H-pyrazol-3-yl;
R1 is H;
R2 is H;
R3 is selected from piperidin-4-yloxy, N-methylpiperidin-4-yloxy, 3-(N-methylcarbamyl)benzyloxy, pyrazin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridimidin-5-ylmethoxy, pyridazin-3-ylmethoxy, and pyrazin-2-ylethoxy; and
R4 is selected from ethynyl, thiazol-2-yl, 1H-pyrazol-4-yl, 1-methyl-1H-pyrazol-4-yl, and 1H-pyrazol-3-yl.
17. The compound according to claim 13, or pharmaceutically acceptable salt thereof, wherein:
A\u2032 is -L2-Ar2;
L2 is \u2014CH2\u2014;
Ar2 is selected from 1,2,4-triazol-1-yl, 1H-pyrazol-1-yl, and 1H-imidazol-1-yl ; each of which is optionally substituted by 1 or 2 independently selected C1-6 alkyl groups;
R1 is H;
R2 is H;
R3 is selected from pyrazin-2-ylmethoxy, pyridin-3-ylmethoxy, pyrazin-2-ylethoxy, and pyrimidin-5-ylmethoxy; and
R3 is selected from \u2014O\u2014CH2-Het and \u2014OCH2\u2014CH2-Het; wherein Het is a pyrazine ring, a pyridine ring, or a pyrimidine ring; which is optionally substituted by a C1-6 alkyl group; and
R4 is selected from C2-6 alkynyl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1-methyl-1H-pyrazol-3-yl, 1-methyl-1H-pyrazol-4-yl, and 1-methyl-1H-pyrazol-5-yl.
18. The compound according to claim 13, or pharmaceutically acceptable salt thereof, wherein:
A\u2032 is -L1-Cy1;
L1 is selected from \u2014CH2\u2014 and \u2014CH2C(\u2550O)\u2014;
Cy1 is selected from morpholin-4-yl; which is optionally substituted by 1 or 2 independently selected C1-6 alkyl groups;
R1 is H;
R2 is H;
R3 is selected from \u2014O\u2014CH2-Het and \u2014OCH2\u2014CH2-Het; wherein Het is a pyrazine ring, a pyridine ring, or a pyrimidine ring; which is optionally substituted by a C1-6 alkyl group; and
R4 is selected from C2-6 alkynyl, 1H-pyrazol-4-yl, 1-methyl-1H-pyrazol-4-yl, and 1H-pyrazol-3-yl.
19. The compound according to claim 13, or pharmaceutically acceptable salt thereof, wherein:
A\u2032 is -L1-Cy1;
L1 is selected from \u2014CH2\u2014 and \u2014CH2C(\u2550O)\u2014;
Cy1 is morpholin-4-yl;
R1 is H;
R2 is H;
R3 is selected from pyrazin-2-ylmethoxy, pyridin-3-ylmethoxy, pyrimidin-5-ylmethoxy, and pyrazin-2-ylethoxy; and
R4 is selected from ethynyl, 1H-pyrazol-4-yl, 1-methyl-1H-pyrazol-4-yl, and 1H-pyrazol-3-yl.
20. The compound according to claim 13, or pharmaceutically acceptable salt thereof, wherein:
A\u2032 is -L1-Cy1;
L1 is \u2014C(\u2550O)\u2014;
Cy1 is selected from a morpholine ring; which is optionally substituted by 1 or 2 independently selected C1-6 alkyl groups;
R1 is H;
R2 is H;
R3 is selected from \u2014O\u2014CH2-Het and \u2014OCH2\u2014CH2-Het; wherein Het is a pyrazine ring; which is optionally substituted by a C1-6 alkyl group; and
R4 is selected from cyano, methyl, C2-6 alkynyl, C3-6 cyclopropyl, 1-methyl-1H-pyrazol-4-yl, 1H-pyrazol-4-yl, and 1H-pyrazol-3-yl.
21. Use of a compound according to any one of claims 1 to 20, for the preparation of medicament for use in a method of treating a cancer selected from lung cancer, bronchial cancer, prostate cancer, breast cancer, pancreatic cancer, colon cancer, rectal cancer, colorectal cancer, thyroid cancer, liver cancer, intrahepatic bile duct cancer, hepatocellular cancer, gastric cancer, gliomaglioblastoma, endometrial cancer, melanoma, kidney cancer, renal pelvic cancer, urinary bladder cancer; uterine corpus cancer; uterine cervical cancer, ovarian cancer, multiple myeloma, esophageal cancer, acute myelogenous leukemia, chronic myelogenous leukemia, lymphocytic leukemia, myeloid leukemia, brain cancer, oral cavity cancer, pharyngeal cancer, laryngeal cancer, small intestinal cancer, non-Hodgkin lymphoma, and villous colon adenoma.
22. Use of a compound according to any one of claims 1 to 20, for the preparation of medicament for use in a method of inhibiting PDK1 or a PDK1 variant in an individual.
23. A compound according to any one of claims 1 to 20, for use in a method Of treating a cancer selected from lung cancer, bronchial cancer, prostate cancer, breast cancer, pancreatic cancer, colon cancer, rectal cancer, colorectal cancer, thyroid cancer, liver cancer, intrahepatic bile duct cancer, hepatocellular cancer, gastric cancer, gliomaglioblastoma, endometrial cancer, melanoma, kidney cancer, renal pelvic cancer, urinary bladder cancer; uterine corpus cancer; uterine cervical cancer, ovarian cancer, multiple myeloma, esophageal cancer, acute myelogenous leukemia, chronic myelogenous leukemia, lymphocytic leukemia, myeloid leukemia, brain cancer, oral cavity cancer, pharyngeal cancer, laryngeal cancer, small intestinal cancer, non-Hodgkin lymphoma, and villous colon adenoma.
24. A compound according to any one of claims 1 to 20, for use in a method of a treating a disease selected from neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis, proliferative diabetic retinopathy, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, angiogenesis and endotoxic shock.
25. A compound according to any one of claims 1 to 20, for use in a method of inhibiting the tumor growth in an individual.
26. A compound according to any one of claims 1 to 20, for use in a method of inhibiting PDK1 or a PDK1 variant in an individual.